5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Association of built environment attributes with the spread of COVID-19 at its initial stage in China

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Evidence of the association of built environment (BE) attributes with the spread of COVID-19 remains limited. As an additional effort, this study regresses a ratio of accumulative confirmed infection cases at the city level in China on both inter-city and intra-city BE attributes. A mixed geographically weighted regression model was estimated to accommodate both local and global effects of BE attributes. It is found that spatial clusters are mostly related to low infections in 28.63 % of the cities. The density of point of interests around railway stations, travel time by public transport to activity centers, and the number of flights from Hubei Province are associated with the spread. On average, the most influential BE attribute is the number of trains from Hubei Province. Higher infection ratios are associated with higher values of between-ness centrality in 70.98 % of the cities. In 79.22 % of the cities, the percentage of the aging population shows a negative association. A positive association of the population density in built-up areas is found in 68.75 % of county-level cities. It is concluded that the countermeasures in China could have well reflected spatial heterogeneities, and the BE could be further improved to mitigate the impacts of future pandemics.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: not found

          The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

          Background: A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities. Objective: To estimate the length of the incubation period of COVID-19 and describe its public health implications. Design: Pooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020. Setting: News reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China. Participants: Persons with confirmed SARS-CoV-2 infection outside Hubei province, China. Measurements: Patient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization. Results: There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection. These estimates imply that, under conservative assumptions, 101 out of every 10 000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine. Limitation: Publicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases. Conclusion: This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS. Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases. Primary Funding Source: U.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humboldt Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

            Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

              The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.
                Bookmark

                Author and article information

                Journal
                Sustain Cities Soc
                Sustain Cities Soc
                Sustainable Cities and Society
                Elsevier Ltd.
                2210-6707
                2210-6715
                3 February 2021
                April 2021
                3 February 2021
                : 67
                : 102752
                Affiliations
                [a ]Mobilities and Urban Policy Lab, Graduate School for International Development and Cooperation, Hiroshima University, Higashi Hiroshima, 739-8529, Japan
                [b ]Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan
                [c ]Prof. Dr. Eng., Mobilities and Urban Policy Lab, Graduate School of Advanced Science and Engineering, Graduate School for International Development and Cooperation, Hiroshima University, Higashi Hiroshima, 739-8529, Japan
                Author notes
                [* ]Corresponding author.
                [1]

                Joint first authors: these authors contributed equally to the work.

                Article
                S2210-6707(21)00046-9 102752
                10.1016/j.scs.2021.102752
                7857111
                33558840
                7878c7c1-65ee-4376-aba9-8b6c39722c1f
                © 2021 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 14 July 2020
                : 19 December 2020
                : 24 January 2021
                Categories
                Article

                covid-19,initial stages of pandemic,china,the built environment,spatial heterogeneity,mixed gwr

                Comments

                Comment on this article